

**INTEGRATION OF IMMUNOTHERAPY INTO ADJUVANT THERAPY FOR RESECTED NSCLC:
ALCHEMIST CHEMO-IO (ACCIO)**

Eligibility Criteria (see Section 3.0)

Resected NSCLC enrolled on A151216
 NSCLC of any histologic subtype
 Stage IIA, IIB, IIIA or IIIB (T3-4N2) per AJCC 8th edition
 Complete R0 resection
 ECOG PS 0-1
 EGFR and ALK negative locally or centrally on A151216
 Candidate for adjuvant platinum-doublet chemotherapy
 Eligible for treatment with an immune checkpoint inhibitor
 30-77 days post-surgery

Required Initial Laboratory Values


Absolute neutrophil count (ANC): $\geq 1500/\text{mm}^3$
 Platelet count: $\geq 100,000/\text{mm}^3$
 Hemoglobin ≥ 8 gm/dl
 Calc. creatinine clearance: ≥ 45 mL/min using the Cockcroft-Gault equation
 Total bilirubin: $\leq 1.5 \times \text{ULN}$

Refer to the full protocol text for a complete description of the eligibility criteria & treatment plan.

FOR PATIENTS CONSENTED ON/AFTER UPDATE #1 POSTING

SCHEMA

1 cycle = 21 days



After the release of Update 07 patients will be randomized to Arms B and C. A081801 previously had an Arm A, in which patients receive a platinum doublet followed by observation.

Patients will be followed for up to 10 years or until death, whichever comes first.

FOR PATIENTS REGISTERED PRIOR UPDATE #1: Patients registered prior to the posting of Update #1 will continue to be treated with pembrolizumab every 3 weeks rather than every 6 weeks. See the Treatment plan in [Section 7.0](#) for further instructions.